CDK4/6 inhibitors, commonly applied to treat breast cancer, are small molecule inhibitors that competitive binding ATP, which inhibit CDK4/6 from forming a complex with Cyclin D and block ATP binding, hence cutting off upstream growth signals and preventing the G1 to S phase transition of cells [97]. This evidence concerns the gene CDK4 and breast cancer.